China

Sinopharm

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

CHINA China

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

COVID-19 Vaccine from China's Sinopharm Clears Animal Tests

Lead Product(s): BBIBP-CorV

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: Phase I/ Phase II Product Type: Vaccine

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 11, 2020

Details:

The vaccine candidate, dubbed BBIBP-CorV and made from an inactivated form of the virus, induced high levels of neutralizing antibodies against SARS-CoV-2—the virus behind COVID-19—in rodents, rabbits and monkeys without triggering any serious adverse event.

I-Mab Biopharma

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

CHINA China

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

I-Mab Reports Interim Results from Part 1 Study for Anti-GM-CSF Antibody TJM2 to Treat COVID-19 Patients with Cytokine Release Syndrome

Lead Product(s): TJM2

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: Phase I/ Phase II Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 28, 2020

Details:

Data monitoring committee (DMC) reviewed the clinical data and unanimously recommended proceeding to part 2 of the study and endorsed the change of low dose treatment arm (3mg/kg) to high dose (6mg/kg).

Sinovac Biotech

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

CHINA China

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Sinovac’s PiCoVacc Experimental Vaccine Shows Promise in Monkeys Infected with SARS-CoV-2

Lead Product(s): PiCoVacc

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: Phase I/ Phase II Product Type: Vaccine

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable April 24, 2020

Details:

Study will evaluate the safety, tolerance, and preliminary immunogenicity of the Sinovac's SARS-CoV-2 vaccine by vaccinating 144 healthy adults, with two different dosages of the vaccine candidate.

Sinovac Biotech

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

CHINA China

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Sinovac Announces Commencement of Phase I Human Clinical Trial for Vaccine Candidate Against COVID-19

Lead Product(s): Inactivated SARS-CoV-2 vaccine

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: Phase I/ Phase II Product Type: Vaccine

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable April 17, 2020

Details:

This study is to evaluate the safety, tolerance, and preliminary immunogenicity of the Company’s SARS-CoV-2 vaccine by vaccinating healthy adults, with two different dosages of the vaccine candidate.

I-Mab Biopharma

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

CHINA China

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Three Research Sites to Lead Clinical Trial of I-Mab’s of TJM2 to Counter COVID-19’s Deadly Cytokine Storm

Lead Product(s): TJM2

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: Phase I/ Phase II Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable April 12, 2020

Details:

I-Mab got by the U.S.FDA to conduct a Phase I clinical trial to assess its investigational product TJM2 to treat cytokine release syndrome associated with severe illness caused by COVID-19.

Find

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Product Type

Companies

Sinopharm

COVID-19 Vaccine from China's Sinopharm Clears Animal Tests

I-Mab Biopharma

I-Mab Reports Interim Results from Part 1 Study for Anti-GM-CSF Antibody TJM2 to Treat COVID-19 Patients with Cytokine Release Syndrome

Sinovac Biotech

Sinovac’s PiCoVacc Experimental Vaccine Shows Promise in Monkeys Infected with SARS-CoV-2

Sinovac Biotech

Sinovac Announces Commencement of Phase I Human Clinical Trial for Vaccine Candidate Against COVID-19

I-Mab Biopharma

Three Research Sites to Lead Clinical Trial of I-Mab’s of TJM2 to Counter COVID-19’s Deadly Cytokine Storm